Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
On 26 August 2008, Michael Totten published the report which contained an interview with an expert Patrick Worms who worked in Tbilisi. Worms's version of events was confirmed by an academic Thomas Goltz. Worms said: "The Ossetians start provoking and provoking and provoking by shelling Georgian positions and Georgian villages around there. And it's a classic tit for tat thing. You shell, I shell back. The Georgians offered repeated ceasefires, which the Ossetians broke. (...) On the 6th of August the shelling intensifies from Ossetian positions. And for the first time since the war finished in 1992, they are using 120mm guns. (...) Because of the peace agreement they had, nobody was allowed to have guns bigger than 80mm. Okay, so that's the formal start of the war. It wasn't the attack on Tskhinvali." In August 2008, Peter Roudik, Senior Foreign Law Specialist working for the Library of Congress, criticized Russian claim that the Georgian attack on Tskhinvali was "an act of aggression" and that the aim of Russian intervention was defence against the Georgian forces, saying that only the United Nations Security Council can identify an act of aggression after studying the causes of the military actions. He pointed out that "an act of aggression requires use of the armed forces of a state against the sovereignty, territorial integrity, or political independence of another state," and that South Ossetia was a part of Georgia on 8 August 2008. This reasoning for Russia's action was questionable since there was no "possibility of Georgian aggression against South Ossetia".
==== Mesenchymal stromal cells (MSCs) ==== Scientists reported 2012 that MSCs when transfused immediately within few hours post thawing may show reduced function or show decreased efficacy in treating diseases as compared to those MSCs which are in log phase of cell growth (fresh), so cryopreserved MSCs should be brought back into log phase of cell growth in in vitro culture before administration. Re-culturing of MSCs will help in recovering from the shock the cells get during freezing and thawing. Various MSC clinical trials which used cryopreserved product immediately post thaw have failed as compared to those clinical trials which used fresh MSCs.
== Epidemiology == Asymptomatic subclinical infection may help spread these diseases, particularly Staphylococcus aureus, Campylobacter, Salmonella, Shigella, Enterobacter, Vibrio cholerae, and Yersinia. For example, as of 1984 it was estimated that in the United States, 200,000 people were asymptomatic carriers of Salmonella.
President Benjamin Asher (Aaron Eckhart) from being killed. The film was a commercial success; however, writing for The A.V. Club, Ignatiy Vishnevetsky criticized the cheap filmmaking, saying: "The movie periodically cuts to overqualified supporting actors—including Freeman, Melissa Leo, and Robert Forster ... (As it turns out, it's possible to write something that will sound like garbage even when spoken in Freeman's sonorous voice.)" Next, Freeman reprised his role as Thaddeus Bradley, starring in Now You See Me 2 (2016), the sequel to Now You See Me, the sequel grossing a successful $334.9 million worldwide. Finally, he had a leading role in the historical drama Ben-Hur, the fifth film adaptation of the 1880 novel Ben-Hur: A Tale of the Christ by Lew Wallace. Freeman expressed interest in playing Sheik Ilderim, a wealthy Nubian sheik, stating: "This character has quite a bit of power in the story. And I like playing power. It's something about my own personal ego." Ben-Hur turned out to be one of 2016's biggest box-office bombs.
=== Use in musical instruments === Birch wood is sometimes used as a tonewood for semiacoustic and acoustic guitar bodies, and occasionally for solid-body guitar bodies. It is also a common material used in mallets for keyboard percussion. Drum manufacturers, such as Gretsch and Yamaha, have been known to use birch wood in the construction of drum shells, owing to its strength and colour which takes stain in an appealing way, and which can also amber over very well, while also giving the drums an appealing tone which changes depending on the type of birch used.
Sources: en.wikipedia.org
Helen Mary Heffernan is a New Zealand microbiologist, specialising in antibiotic resistance. In 2020, she was appointed a Companion of the New Zealand Order of Merit, for services to health. The Institute of Environmental Science and Research awarded Heffernan their Lifetime Achievement Award in 2018.
Individual quick freezing, usually abbreviated IQF, is a descriptive term for freezing methods used in the food processing industry. The food is in individual pieces, and is frozen quickly. Products commonly frozen with IQF technologies are typically smaller pieces of food, and can include berries, fruits and vegetables both diced or sliced, seafood such as shrimp and small fish, meat, poultry, pasta, cheese and grains. Products that have been subjected to IQF are referred to as individually quick frozen.
Traumatic brain injury (TBI): Repairs blood-brain barrier, arrests chronic neurodegeneration, and restores cognition even when administered one year post-injury. Hypoxic-ischemic encephalopathy: Neuroprotective via PI3K/AKT/GSK3β pathway. Alzheimer's disease models: Reverses tau phosphorylation, blood-brain barrier deterioration, oxidative stress, DNA damage, neuroinflammation; enhances neurogenesis and synaptic plasticity; achieves full cognitive recovery. Other models: Protects against ischemic stroke, optic nerve injury, intracerebral hemorrhage, and chemotherapy-induced peripheral neuropathy.
unique DNA Also non-repetitive DNA. A class of DNA sequences determined by C0t analysis to be present only once in the analyzed genome, as opposed to repetitive sequences. Most structural genes and their introns are unique.
Zverev opened his 2019 season with a fourth round appearance at the 2019 Australian Open, defeating Jérémy Chardy in five sets in the second round before losing to Milos Raonic in straight sets. Zverev next played at the Mexican Open and finished runner-up to Nick Kyrgios. Following this tournament, he did not win more than one match at any of his next six events, a streak that ended with two match wins at the Madrid Open. Nonetheless, Zverev finished the clay court season strong. The week before the French Open, he won his only title of the year at the Geneva Open, defeating Nicolás Jarry in the final after saving two match points in the third set tiebreak. He then went on to defeat No. 12 Fabio Fognini and reach his second consecutive quarterfinal at the French Open, where he lost to Novak Djokovic. Zverev did not follow through on that success into the grass court season, where his best result was a quarterfinal at the Halle Open. He was upset in the first round at both the Stuttgart Open and Wimbledon, the latter of which to qualifier Jiří Veselý. Zverev attributed his early season struggles to being distracted by a legal dispute with his former agent Patricio Apey, with whom he had split from in the offseason. Zverev began to turn his season around following Wimbledon. He reached the semifinals of the German Open and the quarterfinals at the Canadian Open. He then reached the last 16 at the US Open for the first time, where he lost to seed No. 20 Diego Schwartzman to continue his lack of success at the major tournaments.
Sources: en.wikipedia.org
The divisions between the elite and the lawless led to the formation of a Cossack army, beginning in 1667 under Stenka Razin, and ultimately to the failure of Razin's rebellion. Stenka Razin was born into an elite Cossack family, and had made many diplomatic visits to Moscow before organizing his rebellion. The Cossacks were Razin's main supporters, and followed him during his first Persian campaign in 1667, plundering and pillaging Persian cities on the Caspian Sea. They returned in 1669, ill and hungry, tired from fighting, but rich with plundered goods. Russia tried to gain support from the old Cossacks, asking the ataman, or Cossack chieftain, to prevent Razin from following through with his plans. But the ataman was Razin's godfather, and was swayed by Razin's promise of a share of expedition wealth. His reply was that the elite Cossacks were powerless against the band of rebels. The elite did not see much threat from Razin and his followers either, although they realized he could cause them problems with the Muscovite system if his following developed into a rebellion against the central government. Razin and his followers began to capture cities at the start of the rebellion, in 1669. They seized the towns of Tsaritsyn, Astrakhan, Saratov, and Samara, implementing democratic rule and releasing peasants from slavery as they went. Razin envisioned a united Cossack republic throughout the southern steppe, in which the towns and villages would operate under the democratic, Cossack style of government.
Glutathione S-transferase Mu 4 is an enzyme that in humans is encoded by the GSTM4 gene. Cytosolic and membrane-bound forms of glutathione S-transferase are encoded by two distinct supergene families. At present, eight distinct classes of the soluble cytoplasmic mammalian glutathione S-transferases have been identified: alpha, kappa, mu, omega, pi, sigma, theta and zeta. This gene encodes a glutathione S-transferase that belongs to the mu class. The mu class of enzymes functions in the detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins and products of oxidative stress, by conjugation with glutathione. The genes encoding the mu class of enzymes are organized in a gene cluster on chromosome 1p13.3 and are known to be highly polymorphic. These genetic variations can change an individual's susceptibility to carcinogens and toxins as well as affect the toxicity and efficacy of certain drugs. Diversification of these genes has occurred in regions encoding substrate-binding domains, as well as in tissue expression patterns, to accommodate an increasing number of foreign compounds. Multiple transcript variants, each encoding a distinct protein isoform, have been identified. In the August 2009 issue of Oncogene journal, researchers at Huntsman Cancer Institute (HCI) at the University of Utah demonstrated that expression levels of GSTM4 could predict response to chemotherapy in patients with Ewing sarcoma. The study found that patients who did not respond to chemotherapy had high levels of GSTM4.
== Side effects == Side effects of THC can include red eyes, dry mouth, drowsiness, short-term memory impairment, difficulty concentrating, ataxia, increased appetite, anxiety, paranoia, psychosis (i.e., hallucinations, delusions), decreased motivation, and time dilation, among others. Chronic usage of THC may result in cannabinoid hyperemesis syndrome (CHS), a condition characterized by cyclic nausea, vomiting, and abdominal pain that may persist for months to years after discontinuation.
{\displaystyle {\hat {H}}={\frac {{\hat {p}}_{x}^{2}+{\hat {p}}_{y}^{2}+{\hat {p}}_{z}^{2}}{2m}}+{\frac {\omega _{c}}{2}}({\hat {x}}{\hat {p}}_{y}-{\hat {y}}{\hat {p}}_{x})+{\frac {1}{2}}m\left({\frac {\omega _{1}}{2}}\right)^{2}({\hat {x}}^{2}+{\hat {y}}^{2})+{\frac {1}{2}}m\omega _{z}^{2}{\hat {z}}^{2}}
=== Generic names === Nicergoline is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.